Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis

References

• World Health Organisation. WHO coronavirus (COVID-19) dashboard [Internet]. [ cited 2022 May 6th]. Available from: https://covid19.who.int
   Google Scholar
• The Vaccine Centre at the London School of Hygiene and Tropical Medicine. Vaccine landscape [internet]. COVID-19 vaccine tracker; 2022 [cited 2022 May 6th]. Available from: https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape
   Google Scholar
• VIPER Group COVID19 Vaccine Tracker Team. COVID19 vaccine tracker [Internet]. [ cited 2022 May 6th]. Available from: https://covid19.trackvaccines.org
   Google Scholar
• Ling Y, Zhong J, and Luo J. Safety and effectiveness of SARS-CoV-2 vaccines: a systematic review and meta-analysis. J Med Virol. 2021 Dec;93(12):6486–6495.
   PubMed Web of Science ®Google Scholar
• Pormohammad A, Zarei M, Ghorbani S, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel) [Internet]. 2021 May 6;9(5). DOI:10.3390/vaccines9050467.
   PubMed Web of Science ®Google Scholar
• Yuan P, Ai P, Liu Y, et al. Safety, tolerability, and immunogenicity of COVID-19 vaccines: a systematic review and meta-analysis. medRxiv [Internet]. 2020 Nov 4. DOI:10.1101/2020.11.03.20224998.
   Google Scholar
• Chen M, Yuan Y, Zhou Y, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty. 2021 Jul 5;10(1):94.
   PubMed Web of Science ®Google Scholar
• Wang J, Tong Y, and Li D, et al. The impact of age difference on the efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021 Dec 6;12:758294.
   PubMed Web of Science ®Google Scholar
• Glanville J, Kotas E, Featherstone R, et al. Which are the most sensitive search filters to identify randomized controlled trials in medline? J Med Libr Assoc. 2020 Oct 1;108(4):556–563.
   PubMed Web of Science ®Google Scholar
• Harrison H, Griffin SJ, Kuhn I, et al. Software tools to support title and abstract screening for systematic reviews in healthcare: an evaluation. BMC Med Res Methodol. 2020 Jan 13;20(1):7.
   PubMed Web of Science ®Google Scholar
• Shrotri M, Swinnen T, Kampmann B, et al. An interactive website tracking COVID-19 vaccine development. Lancet Glob Health. 2021 May;9(5):e590–2.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898.
   PubMed Web of Science ®Google Scholar
• Rohatgi A. WebPlotDigitizer [Internet]. Available from: https://automeris.io/WebPlotDigitizer
   Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021 May 13;384(19):1824–1835.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, and Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021 Dec 16;385(25):2348–2360.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020 Dec 10;383(24):2320–2332.
   PubMed Web of Science ®Google Scholar
• Richmond P, Hatchuel L, Dong M, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021 Feb 20;397(10275):682–694.
   PubMed Web of Science ®Google Scholar
• Meng F-Y, Gao F, Jia S-Y, et al. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther. 2021 Jul 15;6(1):271.
   PubMed Web of Science ®Google Scholar
• Pu J, Yu Q, Yin Z, et al. The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: a phase I randomized, double-blinded, controlled trial. Vaccine. 2021 May 12;39(20):2746–2754.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671–681.
   PubMed Web of Science ®Google Scholar
• Che Y, Liu X, Pu Y, et al. Randomized, double-blinded, placebo-controlled phase 2 trial of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in healthy adults. Clin Infect Dis. 2021 Dec 6;73(11):e3949–55.
   PubMed Web of Science ®Google Scholar
• Zakarya K, Kutumbetov L, Orynbayev M, et al. Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: a single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. E Clin Med. 2021;39:101078.
   Google Scholar
• Ryzhikov AB, Еа R, Bogryantseva MP, et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Infektsiia Immun. 2021 Mar 24;11(2):283–296.
   Web of Science ®Google Scholar
• Thomas SJ, Moreira ED Jr, and Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021 Nov 4;385(19):1761–1773.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, and Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021 Jun 10;384(23):2187–2201.
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021 Jul 6;326(1):35–45.
   PubMed Web of Science ®Google Scholar
• Zhu F, Jin P, and Zhu T, et al. Safety and immunogenicity of a recombinant adenovirus type-5–vectored coronavirus disease 2019 (COVID-19) vaccine with a homologous prime-boost regimen in healthy participants aged ≥6 years: a randomized, double-blind, placebo-controlled, phase 2b trial. Clin Infect Dis [Internet]. 2021 Sep 22:ciab845.
   Web of Science ®Google Scholar
• Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug 15;396(10249):479–488.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022 Jan 15;399(10321):237–248.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug 15;396(10249):467–478.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021 May 20;384(20):1885–1898.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Koen AL, Izu A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 Sep;8(9):e568–80.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979–1993.
   PubMed Web of Science ®Google Scholar
• Asano M, Okada H, Itoh Y, et al. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. Int J Infect Dis. 2022 Jan;114:165–174.
   PubMed Web of Science ®Google Scholar
• Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2022 Mar;22(3):329–340.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021 Jul 15;385(3):239–250.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of Two RNA-Based Covid-19 vaccine candidates. N Engl J Med. 2020 Dec 17;383(25):2439–2450.
   PubMed Web of Science ®Google Scholar
• Haranaka M, Baber J, Ogama Y, et al. A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nat Commun. 2021 Dec 14;12(1):7105.
   PubMed Web of Science ®Google Scholar
• Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021 Dec 9;385(24):2241–2251.
   PubMed Web of Science ®Google Scholar
• Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021 May 12;39(20):2791–2799.
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Baden LR, and Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021 Nov 4;385(19):1774–1785.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis. 2022 Feb;22(2):196–208.
   PubMed Web of Science ®Google Scholar
• Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Jun;21(6):803–812.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb 1;21(2):181–192.
   PubMed Web of Science ®Google Scholar
• Fadlyana E, Rusmil K, Tarigan R, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia. Vaccine. 2021 Oct 22;39(44):6520–6528.
   PubMed Web of Science ®Google Scholar
• Bueno SM, Abarca K, and González PA, et al. Safety and Immunogenicity of an Inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clin Infect Dis [Internet]. 2021 Sep 19:ciab823.
   PubMed Web of Science ®Google Scholar
• Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021 May;21(5):637–646.
   PubMed Web of Science ®Google Scholar
• Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021 Dec 11;398(10317):2173–2184.
   PubMed Web of Science ®Google Scholar
• Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021 Sep 23;385(13):1172–1183.
   PubMed Web of Science ®Google Scholar
• Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021 May 20;384(20):1899–1909.
   PubMed Web of Science ®Google Scholar
• Formica N, Mallory R, Albert G, et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLoS Med. 2021 Oct;18(10):e1003769.
   PubMed Web of Science ®Google Scholar
• Dunkle LM, Kotloff KL, and Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022 Feb 10;386(6):531–543.
   PubMed Web of Science ®Google Scholar
• Hsieh S-M, Liu M-C, Chen Y-H, et al. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respir Med. 2021 Dec;9(12):1396–1406.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 Jan;21(1):39–51.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doğanay HL, and Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213–222.
   PubMed Web of Science ®Google Scholar
• Guo W, Duan K, Zhang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine. 2021 Aug;38:101010.
   PubMedGoogle Scholar
• Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021 Aug;21(8):1107–1119.
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu Z, He J, et al. Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial. Emerg Microbes Infect. 2021 Dec;10(1):1589–1597.
   PubMed Web of Science ®Google Scholar
• Shu Y-J, He J-F, Pei R-J, et al. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial. Chin Med J. 2021 Jul 22;134(16):1967–1976.
   PubMed Web of Science ®Google Scholar
• Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Dec;21(12):1645–1653.
   PubMed Web of Science ®Google Scholar
• Haas JW, Bender FL, Ballou S, et al. Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: a systematic review and meta-analysis. JAMA Network Open. 2022 Jan 4;5(1):e2143955.
   PubMed Web of Science ®Google Scholar
• Bonhoeffer J, Kohl K, Chen R, et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine. 2002 Dec 13;21(3–4):298–302.
   PubMed Web of Science ®Google Scholar